Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference5 articles.
1. Wu Y, Gao Y, Li Q, Wu C, Xie E, Tu Y, Guo Z, Ye Z, Li P, Li Y, Yu X, Ren J, Zheng J. Predictive Value of the CHA(2)DS(2)-VASc score for mortality in hospitalized acute coronary syndrome patients with chronic kidney disease. Front Cardiovasc Med. 2022;9:790193.
2. Cetinkal G, Kocas BB, Ser OS, Kilci H, Keskin K, Ozcan SN, Verdi Y, Zeren MI, Demir T, Kilickesmez K. Assessment of the modified CHA2DS2VASc risk score in predicting mortality in patients hospitalized with COVID-19. Am J Cardiol. 2020;135:143–9.
3. Lohrmann GLA, Ziegler P, Monteiro J, Varberg N, Passman R. CHA2DS2VASc Score as a predictor of ablation success defined by continuous long-term monitoring. J Int Cardiac Electrophysiol. 2022. https://doi.org/10.1007/s10840-022-01326-6
4. Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L, Leong-Sit P, Novak P, Badra-Verdu M, Sapp J, Mangat I, Khoo C, Steinberg C, Bennett MT, Tang ASL, Khairy P. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation. 2019;140:1779–88.
5. Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatric Cardiol : JGC. 2013;10:258–66.